The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Open accessAbstract
Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.Methods KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031.Findings Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis. Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis. At final analysis, grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group, 235 (85%) of 276 in the pembrolizumab with chemotherapy group, and 239 (83%) of 287 in the cetuximab with chemotherapy group. Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.Interpretation Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.Funding Merck Sharp & Dohme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of two fatal cases of myocarditis showed overexpression of cardiac proteins in the tumors of the affected patients, also potentially suggesting an overlap.18”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationPlatinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Cohen, E. E. W., Soulières, D., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,737
Self-citationHead and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S. S., Adelstein, D. J., Adkins, D. R., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,377
Self-citationThe Efficiency of Cox's Likelihood Function for Censored Data
Efron, B. (1977) · Journal of the American Statistical Association · doi:10.1080/01621459.1977.10480613 · Cited by 1,240
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Wolkow, N., Jakobiec, F. A., Afrogheh, A., Pai, S. I., & Faquin, W. C. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.07.031 · Cited by 17
Held, T., Lang, K., Regnery, S., Weusthof, K., Hommertgen, A., Jäkel, C., Tonndorf‐Martini, E., Krisam, J., Plinkert, P. K., Zaoui, K., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01625-0 · Cited by 16
Ueda, Y., Enokida, T., Okano, S., Fujisawa, T., Ito, K., & Tahara, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.571304 · Cited by 16
Self-citationThe Inequitable Global Burden of Lip and Oral Cancers: Widening Disparities Across Countries
Harris, J. A., Ritchie, C. A., Hanna, G. J., McCain, J. P., & Ji, Y. D. (2020) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2020.12.035 · Cited by 15
Franz, L., Alessandrini, L., Calvanese, L., Crosetta, G., Frigo, A. C., & Marioni, G. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.007 · Cited by 16
Keukeleire, S. D., Vermassen, T., Meulenaere, A. D., Deron, P. B., Huvenne, W., Duprez, F., Creytens, D., Dorpe, J. V., Rottey, S., & Ferdinande, L. (2021) · Pathology · doi:10.1016/j.pathol.2021.03.005 · Cited by 16
Falco, A. H., de Oliveira, T. B., Cacicedo, J., Ospina, A. V., Ticona, M. A., Galindo, H., Pereira, M. D., Aguilar-Ponce, J. L., Rueda‐Domínguez, A., Soria, T., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s322411 · Cited by 16
Self-citationMismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
Hieggelke, L., Heydt, C., Castiglione, R., Rehker, J., Merkelbach‐Bruse, S., Riobello, C., Llorente, J. L., Hermsen, M. A. J. A., & Buettner, R. (2021) · Cancers · doi:10.3390/cancers13236081 · Cited by 16
Chen, L., Mo, D., Hu, M., Zhao, S.-J., Yang, Q.-W., & Huang, Z.-L. (2021) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2021.103324 · Cited by 16
Okamoto, I., Tsukahara, K., & Sato, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-06084-z · Cited by 16
Glazar, D. J., Johnson, M., Farinhas, J. M., Steuer, C. E., Saba, N. F., Bonomi, M. R., Chung, C. H., & Enderling, H. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105787 · Cited by 16
Chiang, N.-J., Tan, K. T., Bai, L., Hsiao, C., Huang, C., Hung, Y., Huang, C., Chen, S., Shan, Y., Chao, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1152 · Cited by 16
Self-citationMatoba, T., Minohara, K., Kawakita, D., Takano, G., Oguri, K., Murashima, A., Nakai, K., Iwaki, S., Tsuge, H., Tanaka, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18611-z · Cited by 16
Franz, L., Alessandrini, L., Ottaviano, G., Carlo, R. D., Fasanaro, E., Ramacciotti, G., Contro, G., & Marioni, G. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153120 · Cited by 16
Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
Stern, P. L., & Dalianis, T. (2021) · Viruses · doi:10.3390/v13071234 · Cited by 16
Park, J., Ye, G. H., Merkin, R. D., & Roberts, T. J. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf043 · Cited by 15
Yang, W., Guo, Z., Ju, H., Lu, Y., Fei, Y., Yin, Y., Ren, G., Yan, M., Han, C., & Hu, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011474 · Cited by 15
Khaw, M. J., Zorko, N. A., Kennedy, P. R., Bendzick, L. E., Shackelford, M., Selleck, C., Hinderlie, P., Walker, J. T., Soignier, Y., Lyons, R. C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011370 · Cited by 15
Zhang, B., Tan, H., Kuang, J., Zhou, B., Liang, S., Pang, X. Y., Ouyang, Y., Zhang, Z., Long, Y., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02487-4 · Cited by 15
Cancer patients in SARS-CoV-2 infection: a single-center experience from Wuhan
Wang, J., Zhang, J., Tu, Y., Zhou, X., Huang, H., Shao, L., Chen, L., Zhao, Y. D., & Ge, M. (2020) · Journal of Cancer · doi:10.7150/jca.47065 · Cited by 15
Specenier, P. M. (2021) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000700 · Cited by 15
Moratin, J., Möck, A., Obradovic, S., Metzger, K., Flechtenmacher, C., Zaoui, K., Fröhling, S., Jäger, D., Krauß, J., Hoffmann, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712944 · Cited by 15
Sarı, S. Y., Yılmaz, M. T., Aktaş, B. Y., Aksoy, S., Güllü, İ., Cengiz, M., Özyiğit, G., & Yazıcı, G. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105658 · Cited by 15
Self-citationYang, C., Lien, C., Hwang, T., Wang, C.-C., Wang, C., Shih, Y., Yeh, S., & Hsieh, M. (2022) · Cancers · doi:10.3390/cancers14102351 · Cited by 15
Self-citationConstruction of an immune infiltration landscape based on immune-related genes in cervical cancer
Yang, Y., Wang, N., Shi, X., Wang, Y., Yang, C., Fan, J., & Jia, X. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105638 · Cited by 15
Emerging tyrosine kinase inhibitors for head and neck cancer
Long, Z., Grandis, J. R., & Johnson, D. E. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2125954 · Cited by 16
William, W. N., Zhang, J. J., Zhao, X., Parra, E. R., Uraoka, N., Lin, H. Y., Peng, S. A., El‐Naggar, A. K., Rodriguez‐Canales, J., Song, J., et al. (2023) · Cancer · doi:10.1002/cncr.34607 · Cited by 15
The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
Shi, M.-Y., Liu, H.-G., Chen, X.-H., Tian, Y., Chen, Z., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088886 · Cited by 15
Zhang, Y., Yao, Q., Pan, Y., Fang, X., Xu, H., Zhao, T., Zhu, G., Jiang, T., Li, S., & Cao, H. (2023) · Cancers · doi:10.3390/cancers15030682 · Cited by 18
Self-citationHighlights into historical and current immune interventions for cancer
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15
Head and neck cancer treatment in the era of molecular medicine
Pandruvada, S. N. M., Kessler, R., & Thai, A. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.004 · Cited by 17
Güven, D. C., Stephen, B., Şahin, T. K., Çakır, İ. Y., & Aksoy, S. (2023) · The Laryngoscope · doi:10.1002/lary.30754 · Cited by 16
Self-citationNieto, C., Miller, B., Alzofon, N., Chimed, T., Himes, J., Joshi, M. U., Gomez, K. E., Chowdhury, F. N., Le, P. N., Weaver, A. N., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad126 · Cited by 15
Sakai, A., Ebisumoto, K., Iijima, H., Yamauchi, M., Teramura, T., Yamazaki, A., Watanabe, T., Inagi, T., Maki, D., & Okami, K. (2023) · Discover Oncology · doi:10.1007/s12672-023-00774-4 · Cited by 15
Self-citationNguyen, K. A., DePledge, L., Bian, L., Ke, Y., Samedi, V., Berning, A. A., Owens, P., Wang, X., & Young, C. D. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007110 · Cited by 15
Bakema, J. E., van Walsum, M., Harris, J. R., Ganzevles, S. H., Muthuswamy, A., Houtkamp, M., Plantinga, T. S., Bloemena, E., Brakenhoff, R. H., Breij, E. C. W., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0298 · Cited by 15
Sannigrahi, M. K., Cao, A. C., Rajagopalan, P., Sun, L., Brody, R. M., Raghav, L., Gimotty, P. A., & Basu, D. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13558 · Cited by 15
Ishihara, H., Nishikawa, D., Muraoka, D., Masago, K., Beppu, S., Terada, H., Matsushita, H., & Hanai, N. (2023) · Cancer Medicine · doi:10.1002/cam4.6863 · Cited by 15
Self-citationCombinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer
Tan, J. S. H., Tay, T. K. Y., Ong, E. H. W., Fehlings, M., Tan, D. S.-W., Sukma, N. B., Chen, E. X., Sng, J.-H., Yip, C., Lim, K. H., et al. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0144 · Cited by 17
Hanyu, K., Okamoto, I., Tokashiki, K., & Tsukahara, K. (2024) · Case Reports in Oncology · doi:10.1159/000536166 · Cited by 15
The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
Kranjčević, J.-K., Čonkaš, J., & Ozretić, P. (2024) · Cancers · doi:10.3390/cancers16081575 · Cited by 22
Hirakawa, H., Ikegami, T., Kinjyo, H., HAYASHI, Y., Agena, S., Higa, T., Kondo, S., Toyama, M., Maeda, H., & Suzuki, M. (2024) · Anticancer Research · doi:10.21873/anticanres.17218 · Cited by 15
Tian, X., Zhang, H., Han, Y., Gu, B., & Zhang, Z. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102864 · Cited by 15
Wang, Y., Chen, F., Ouyang, Z., He, S., Qin, X., Xian, L., Huang, W., Wang, R., & Hu, K. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102245 · Cited by 15
The 5-Ws of immunotherapy in head and neck cancer
Botticelli, A., Mezi, S., Pomati, G., Cerbelli, B., Rocco, C. D., Amirhassankhani, S., Sirgiovanni, G., Occhipinti, M. A., Napoli, V. M., Emiliani, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103041 · Cited by 15
Schubert, P., Rutzner, S., Eckstein, M., Frey, B., Schweizer, C., Haderlein, M., Lettmaier, S., Semrau, S., Gostian, A., Zhou, J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576643 · Cited by 17
Digitalized healthcare for head and neck cancer patients
Bouaoud, J., Bertolus, C., Zrounba, P., & Saintigny, P. (2020) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2020.11.003 · Cited by 17
Qaraghuli, M. M. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.559596 · Cited by 15
Xu, J., Xu, N., Bai, Y., Liu, R., Mao, C., Sui, H., Wang, X., Jiang, Q., & Dou, Y. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1864908 · Cited by 15
Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma
Okada, T., Okamoto, I., Sato, H., Ito, T., Miyake, K., & Tsukahara, K. (2021) · In Vivo · doi:10.21873/invivo.12376 · Cited by 15
Arends, R. H., Guo, X., Baverel, P., González-García, I., Xie, J., Morsli, N., Yovine, A. J., & Roskos, L. K. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1898104 · Cited by 15
Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
Denis, C., Sakalihasan, S., Frères, P., Withofs, N., & Sautois, B. R. (2021) · Case Reports in Oncology · doi:10.1159/000517008 · Cited by 15
Immunotherapy for HPV Malignancies
Lee, M. Y., & Allen, C. T. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.02.008 · Cited by 17
Targeted gene expression profiling of inverted papilloma and squamous cell carcinoma
Tong, C. C. L., Koptyra, M., Raman, P., Rathi, K. S., Choudhari, N., Lin, X., Seckar, T. D., Wei, Z., Kohanski, M. A., O'Malley, B. W., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22882 · Cited by 15
Muniz, T. P., Araújo, D. V., Savage, K. J. J., Cheng, T., Saha, M., Song, X., Gill, S., Monzon, J. G., Grenier, D., Genta, S., et al. (2021) · Cancers · doi:10.3390/cancers14010089 · Cited by 15
Burman, B., Drutman, S. B., Fury, M. G., Wong, R. J., Katabi, N., Ho, A. L., & Pfister, D. G. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105806 · Cited by 15
Baldi, G. G., Gronchi, A., Tazzari, M., & Stacchiotti, S. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2065986 · Cited by 15
Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
Wang, J., Ma, X., Ma, Z., Ma, Y., Wang, J., & Cao, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810539 · Cited by 14
Saito, Y., Fujiwara, Y., Shinchi, Y., Mito, R., Miura, Y., Yamaguchi, T., Ikeda, K., Urakami, S., Nakashima, Y., Sakagami, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15442 · Cited by 16
Gan, C. P., Lee, B. K. B., Lau, S. H., Kallarakkal, T. G., Zaini, Z. M., Lye, B. K. W., Zain, R. B., Sathasivam, H. P., Yeong, J. P.-S., Savelyeva, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954567 · Cited by 15
Odeny, T., Lurain, K. A., Strauss, J., Fling, S. P., Sharon, E., Wright, A., Martínez‐Picado, J., Morán, T., Gulley, J. L., González‐Cao, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005128 · Cited by 15
Chen, Z., John, J., & Wang, J. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.995434 · Cited by 19
Matsubara, Y., Toriyama, K., Kadowaki, S., Ogata, T., Nakazawa, T., Kato, K., Nozawa, K., Narita, Y., Honda, K., Masuishi, T., et al. (2023) · Esophagus · doi:10.1007/s10388-022-00978-7 · Cited by 15
Sherman, E. J., Lee, J. L., Debruyne, P. R., Keam, B., Shin, S. J., Gramza, A. W., Caro, I., Amin, R., Shah, K., Yan, Y., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100877 · Cited by 15
Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review
Tamimi, A., Tamimi, A., Sorkheh, F., Asl, S. M., Ghafari, A., Karimi, A. G., Erabi, G., Pourmontaseri, H., & Deravi, N. (2023) · Cancer Reports · doi:10.1002/cnr2.1802 · Cited by 16
Yang, Y., & Xu, G. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05922-w · Cited by 15
Gui, S., O’Neill, W. Q., Teknos, T. N., & Pan, Q. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001259 · Cited by 14
Immunotherapy Management in Special Cancer Patient Populations
Ramnaraign, B. H., Chatzkel, J. A., Al‐Mansour, Z., Rogers, S. C., Jones, D. V., DeRemer, D. L., & George, T. J. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00996 · Cited by 15
An, P.-G., Wu, W., Hu, X., Zhang, Z., & Zhang, J. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04014-2 · Cited by 14
ANO1: central role and clinical significance in non-neoplastic and neoplastic diseases
Hu, Y., Zhang, Y., He, J., Rao, H., Zhang, D., Shen, Z., & Zhou, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1570333 · Cited by 15
Self-citationLuo, J., Zhi, Q., Li, D., Xu, Y., Zhu, H., Zhao, L., Ren, G., Wang, J., & Liu, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1558814 · Cited by 14
Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC
Mastrolonardo, E. V., Ravin, E. D., Kaki, P. C., Estephan, L. E., Nunes, K. L., Kenny, H. L., Bridgham, K., Tasoulas, J., Koeneman, S., Goldman, R. A., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2025.4573 · Cited by 14
Hua, Y., Dong, R., Jin, T., Jin, Q., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.781348 · Cited by 14
Chao, Y., Jiang, W., Wang, X., Wang, X., Song, J., Chen, C., Zhou, J., Huang, Q., Hu, J., & Song, Y. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac021 · Cited by 14
Preoperative immunotherapy for head and neck cancers: state of art
Egloff, A. M., & Uppaluri, R. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000826 · Cited by 14
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss
Lalonde, C. S., Teng, Y., Burtness, B. A., Ferris, R. L., Ahmed, R., & Saba, N. F. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac098 · Cited by 14
Self-citationConcordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
Keukeleire, S. D., Vermassen, T., Deron, P. B., Huvenne, W., Duprez, F., Creytens, D., Dorpe, J. V., Ferdinande, L., & Rottey, S. (2022) · Cancers · doi:10.3390/cancers14102431 · Cited by 14
Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
Irabor, O. C., Nelson, N. G., Shah, Y., Niazi, M. Z., Poiset, S., Storozynsky, E., Singla, D. K., Hooper, D. C., & Lu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940127 · Cited by 14
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory
Sezen, D., Barsoumian, H. B., He, K., Hu, Y. Y., Wang, Q., Abana, C. O., Puebla‐Osorio, N., Hsu, E. Y., Wasley, M. D., Masrorpour, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984318 · Cited by 15
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Horowitch, B., Lee, D. Y., Ding, M., Martínez-Morilla, S., Aung, T. N., Ouerghi, F., Wang, X., Wei, W., Damsky, W., Sznol, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0215 · Cited by 14
Sharon, S., Daher-Ghanem, N., Zaid, D., Gough, M. J., & Kravchenko‐Balasha, N. (2023) · Frontiers in Oral Health · doi:10.3389/froh.2023.1180869 · Cited by 16
Pakkanen, P., Ilmarinen, T. T., Halme, E., Irjala, H., Koivunen, P. T., Pukkila, M. J., Ventelä, S., Almangush, A., Birkman, E., Lindgren, O., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03586-7 · Cited by 14
Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma
Hsieh, C.-Y., Lin, C., & Chang, W. (2023) · Biomedicines · doi:10.3390/biomedicines11112887 · Cited by 14
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
Miedema, I. H. C., Wijngaarden, J. E., Pouw, J. E. E., Zwezerijnen, G. J. C., Sebus, H. J., Smit, E. F., Langen, A. J. D., Bahce, I., Thiele, A., Vugts, D. J., et al. (2023) · Cancers · doi:10.3390/cancers15235546 · Cited by 14
Omori, Y., Noguchi, K., Kitamura, M., Makihara, Y., Omae, T., Hanawa, S., Yoshikawa, K., Takaoka, K., & Kishimoto, H. (2024) · Cancers · doi:10.3390/cancers16020343 · Cited by 14
Perioperative immunotherapy for esophageal squamous cell carcinoma
Wei, D. D., Fang, J. M., Wang, H., Chen, J., Kong, S., Jiang, Y., & Jiang, Y. Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330785 · Cited by 17
Self-citationUpadhyay, R., Gogineni, E., Tocaj, G., Ma, S. J., Bonomi, M. R., Bhateja, P., Konieczkowski, D. J., Baliga, S., Mitchell, D., Jhawar, S. R., et al. (2024) · Cancers · doi:10.3390/cancers16051049 · Cited by 14
Immunotherapy for head and neck cancer: Fundamentals and therapeutic development
Okano, S. (2024) · Auris Nasus Larynx · doi:10.1016/j.anl.2024.05.001 · Cited by 15
Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma
Mastrolonardo, E. V., Llerena, P., Lu, J. S., Nunes, K. L., Choi, G. K., Amin, D. R., Bridgham, K., Campbell, D., Philips, R. H. W., Cognetti, D. M., et al. (2024) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.1568 · Cited by 14
Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma
Britton, W. R., Cioffi, I., Stonebraker, C., Spence, M. D. A., Okolo, O. B., Martin, C., Henick, B. S., Nakagawa, H., & Parikh, A. S. (2024) · Cancers · doi:10.3390/cancers16173047 · Cited by 14
Belfiore, M. P., Nardone, V., D’Onofrio, I., Pirozzi, M., Sandomenico, F., Farese, S., Chiara, M. D., Balbo, C., Cappabianca, S., & Fasano, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092080 · Cited by 14
Mastrolonardo, E. V., Nunes, K. L., Llerena, P., Nikitina, A. S., Sobol, A., Scott, E. R., Tuluc, M., Davitt, C. J. H., Scher, J., Tekumalla, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0037 · Cited by 15
The ending is not the end: Lymph node metastasis in oral squamous cell carcinoma
Wei, L.-Y., Li, Z., Xu, Z.-Y., Wang, G.-R., Xiao, Y., Liu, B., & Bu, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113917 · Cited by 16
Henick, B. S., Taylor, A. M., Nakagawa, H., Wong, K., Diehl, J. A., & Rustgi, A. K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.003 · Cited by 17
Self-citationZhou, K., Li, Y., Liao, W., Zhang, M., Bai, L., & Li, Q. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104754 · Cited by 14
New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2019
Rameau, A., Hong, R., Djalilian, H. R., Erbele, I. D., Phillips, K. M., Capasso, R., Rose, A. S., Brenner, M. J., & Maria, P. L. S. (2020) · OTO Open · doi:10.1177/2473974x20932506 · Cited by 14
Self-citationPflumio, C., Thomas, J., Salleron, J., Faivre, J.-C., Borel, C., Dolivet, G., Sastre‐Garau, X., & Geoffrois, L. (2021) · Oncology Reports · doi:10.3892/or.2021.7928 · Cited by 14
Evaluation of prognostic biomarkers in a population-validated Finnish HNSCC patient cohort
Routila, J., Leivo, I. V. V., Minn, H. R. I., Westermarck, J. K., & Ventelä, S. (2021) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-06650-7 · Cited by 14
Gingival Leukoplakia: Hyperkeratosis with Epithelial Atrophy Is A Frequent Histopathologic Finding
Alabdulaaly, L., Almazyad, A., & Woo, S. (2021) · Head and Neck Pathology · doi:10.1007/s12105-021-01333-5 · Cited by 15
Tian, Y., Li, R., Liu, Y., Li, M., Song, Y., Zheng, Y., Gao, A., Wen, Q., Su, G., & Sun, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667650 · Cited by 14
Metadata
- Authors
- Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R.-L., González Mendoza, R., Roy, A., Zhang, Y., Gumuscu, B., Cheng, J. D., Jin, F., Rischin, D., Lerzo, G., Tatangelo, M., Varela, M., Zarba, J. J., Boyer, M., Gan, H., Gao, B., Hughes, B., Mallesara, G., Rischin, D., Taylor, A., Burian, M., Fuereder, T., Greil, R., Barrios, C. H., de Castro Junior, D. O., Castro, G., Franke, F. A., Girotto, G., Lima, I. P. F., Nicolau, U. R., Pinto, G. D. J., Santos, L., Victorino, A.-P., Chua, N., Couture, F., Gregg, R., Hansen, A., Hilton, J., McCarthy, J., Soulieres, D., Ascui, R., Gonzalez, P., Villanueva, L., Torregroza, M., Zambrano, A., Holeckova, P., Kral, Z., Melichar, B., Prausova, J., Vosmik, M., Andersen, M., Gyldenkerne, N., Jurgens, H., Putnik, K., Reinikainen, P., Gruenwald, V., Laban, S., Aravantinos, G., Boukovinas, I., Georgoulias, V., Psyrri, A., Kwong, D., Al-Farhat, Y., Csoszi, T., Erfan, J., Horvai, G., Landherr, L., Remenar, E., Ruzsa, A., Szota, J., Billan, S., Gluck, I., Gutfeld, O., Popovtzer, A., Benasso, M., Bui, S., Ferrari, V., Licitra, L., Nole, F., Fujii, T., Fujimoto, Y., Hanai, N., Hara, H., Matsumoto, K., Mitsugi, K., Monden, N., Nakayama, M., Okami, K., Oridate, N., Shiga, K., Shimizu, Y., Sugasawa, M., Tahara, M., Takahashi, M., Takahashi, S., Tanaka, K., Ueda, T., Yamaguchi, H., Yamazaki, T., Yasumatsu, R., Yokota, T., Yoshizaki, T., Kudaba, I., Stara, Z., Wan Ishak, W. Z., Cheah, S. K., Aguilar Ponce, J., Gonzalez Mendoza, R., Hernandez Hernandez, C., Medina Soto, F., Buter, J., Hoeben, A., Oosting, S., Suijkerbuijk, K., Bratland, A., Brydoey, M., Alvarez, R., Mas, L., Caguioa, P., Querol, J., Regala, E. E., Tamayo, M. B., Villegas, E. M., Kawecki, A., Karpenko, A., Klochikhin, A., Smolin, A., Zarubenkov, O., Goh, B. C., Cohen, G., du Toit, J., Jordaan, C., Landers, G., Ruff, P., Szpak, W., Tabane, N., Brana, I., Iglesias Docampo, L., Lavernia, J., Mesia, R., Abel, E., Muratidu, V., Nielsen, N., Cristina, V., Rordorf, T., Rothschild, S., Hong, R.-L., Wang, H.-M., Yang, M.-H., Yeh, S.-P., Yen, C.-J., Ngamphaiboon, N., Soparattanapaisarn, N., Sriuranpong, V., Aksoy, S., Cicin, I., Ekenel, M., Harputluoglu, H., Ozyilkan, O., Harrington, K., Agarwala, S., Ali, H., Alter, R., Anderson, D., Bruce, J., Burtness, B., Campbell, N., Conde, M., Deeken, J., Edenfield, W., Feldman, L., Gaughan, E., Goueli, B., Halmos, B., Hegde, U., Hunis, B., Jotte, R., Karnad, A., Khan, S., Laudi, N., Laux, D., Martincic, D., McCune, S., McGaughey, D., Misiukiewicz, K., Mulford, D., Nadler, E., Neupane, P., Nunnink, J., Ohr, J., O'Malley, M., Patson, B., Paul, D., Popa, E., Powell, S., Redman, R., Rella, V., Rocha Lima, C., Sivapiragasam, A., Su, Y., Sukari, A., Wong, S., Yilmaz, E., & Yorio, J.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Oslo University Hospital (NO)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Mahidol University (TH)
- Paracelsus Medical University (AT)
- National Cancer Center Hospital East (JP)
- The University of Melbourne (AU)
- Autonomous University of Chihuahua (MX)
- ORCID
- Basté, Neus
- Bratland, Åse
- Roy, Ananya
- Jin, Fan
- Boyer, Michael
- Gan, Hui
- Gao, Bo
- Mallesara, Girish
- Burian, Martin
- Barrios, Carlos Henrique
- Franke, Fabio Andre
- Girotto, Gustavo
- Nicolau, Ulisses Ribaldo
- Pinto, Gustavo Dix Junqueira
- Santos, Lucas
- Victorino, Ana-Paula
- Chua, Neil
- Gregg, Richard
- Hansen, Aaron
- Hilton, John
- Zambrano, Angela
- Melichar, Bohuslav
- Andersen, Maria
- Reinikainen, Petri
- Laban, Simon
- Aravantinos, Gerasimos
- Boukovinas, Ioannis
- Billan, Salem
- Popovtzer, Aron
- Bui, Simona
- Licitra, Lisa
- Fujii, Takashi
- Fujimoto, Yasushi
- Hanai, Nobuhiro
- Hara, Hiroki
- Matsumoto, Koji
- Monden, Nobuya
- Nakayama, Masahiro
- Okami, Kenji
- Oridate, Nobuhiko
- Shiga, Kiyoto
- Shimizu, Yasushi
- Sugasawa, Masashi
- Takahashi, Masanobu
- Takahashi, Shunji
- Tanaka, Kaoru
- Ueda, Tsutomu
- Yamaguchi, Hironori
- Yamazaki, Tomoko
- Yasumatsu, Ryuji
- Yokota, Tomoya
- Yoshizaki, Tomokazu
- Buter, Jan
- Hoeben, Ann
- Oosting, S.
- Suijkerbuijk, Karijn
- Mas, Luis
- Caguioa, Priscilla
- Kawecki, Andrzej
- Klochikhin, Arkadiy
- Smolin, Alexey
- Goh, Boon Cher
- Cohen, Graham
- Ruff, Paul
- Szpak, Waldemar
- Lavernia, Javier
- Abel, Edvard
- Rothschild, Sacha
- Wang, Hung-Ming
- Yang, Muh-Hwa
- Yeh, Su-Peng
- Yen, Chia-Jui
- Sriuranpong, Virote
- Aksoy, Sercan
- Ekenel, Meltem
- Agarwala, Sanjiv
- Ali, Haythem
- Alter, Robert
- Anderson, Daniel
- Bruce, Justine
- Campbell, Nicholas
- Conde, Miguel
- Deeken, John
- Feldman, Lawrence
- Gaughan, Elizabeth
- Hegde, Upendra
- Jotte, Robert
- Karnad, Anand
- Khan, Saad
- Laudi, Noel
- Laux, Douglas
- McCune, Steven
- Misiukiewicz, Krzysztof
- Nadler, Eric
- Ohr, James
- Paul, Doru
- Powell, Steven
- Sivapiragasam, Abirami
- Sukari, Ammar
- Wong, Stuart
- Yilmaz, Emrullah
- Yorio, Jeffrey
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 394
- Issue
- 10212
- Pages
- 1915-1928
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2986633517
- Cited by
- 3,336
- References
- 25
- Citations by year
- 2026: 434 · 2025: 551 · 2024: 549 · 2023: 522 · 2022: 535 · 2021: 465 · 2020: 270 · 2019: 5
- FWCI
- 268.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Eisai
- Japan Society for the Promotion of Science (17H01590, 17K19718)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- cetuximab, head and neck squamous cell carcinoma, recurrent or metastatic cancer, PD-L1 expression, PD-L1 combined positive score, immune checkpoint inhibitors, overall survival, progression-free survival, non-inferiority, p16 status, treatment safety
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Squamous Cell Carcinoma of Head and Neck, Progression-Free Survival, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
